VEXAS综合征患者中发现的新型体细胞UBA1变异
报告一例59岁欧洲裔男性,有2年关节炎、发热、盗汗、非特异性皮疹、淋巴结病及伴多系发育异常的骨髓增生异常综合征病史,基因分析发现UBA1基因外显子14的先前未描述变异c.1430G>C(p.Gly477Ala),体外酶学分析显示该变异导致E1泛素硫酯形成减少和E2酶装载减少,因对多种免疫抑制治疗反应不足而接受异基因造血干细胞移植后临床和实验室表现显著改善。
要点
- VEXAS综合征患者中发现了先前未描述的UBA1基因外显子14变异c.1430G>C(p.Gly477Ala)。
- 体外酶学分析显示p.Gly477Ala导致E1泛素硫酯形成减少和E2酶装载减少。
- 患者对多种免疫抑制治疗反应不足,异基因造血干细胞移植后临床和实验室表现显著改善。
核心结论
- 报告一例欧洲裔VEXAS综合征患者,与一个新鉴定的功能失调UBA-1酶变异相关。
- 患者对多种免疫抑制治疗反应不足,异基因造血干细胞移植后疾病临床和实验室表现显著改善。
研究设计与样本
- 病例研究,分析一名59岁男性的临床、生化和分子遗传学特征。
主要发现
- 患者为59岁男性,有2年关节炎、发热、盗汗、非特异性皮疹、淋巴结病及伴多系发育异常的骨髓增生异常综合征病史。
- 突变分析发现UBA1基因外显子14中先前未描述的序列变异c.1430G>C(p.Gly477Ala)。
- 体外酶学分析显示p.Gly477Ala导致E1泛素硫酯形成减少和E2酶装载减少。
关键数值与推荐
- 直接测序分析包含流行变异p.Met41Leu、p.Met41Val和/或p.Met41Thr的外显子3通常用于确认疾病相关突变。
临床怎么用
- 患者因对多种免疫抑制治疗反应不足而接受异基因造血干细胞移植,移植后疾病临床和实验室表现显著改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Somatic mutations in UBA1 have recently been causally linked to a severe adult-onset inflammatory condition referred to as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. Ubiquitin-activating enzyme E1 (UBA-1) is of fundamental importance to the modulation of ubiquitin homeostasis and to the majority of downstream ubiquitylation-dependent cellular processes. Direct sequencing analysis of exon 3 containing the prevalent variants p.Met41Leu, p.Met41Val, and/or p.Met41Thr is usually used to confirm the disease-associated mutations. METHODS: We studied the clinical, biochemical, and molecular genetic characteristics of a 59-year-old man with a 2-year history of arthritis, fever, night sweats, nonspecific skin rash, lymphadenopathy, and myelodysplastic syndrome with multilineage dysplasia. RESULTS: The mutational analysis revealed a previously undescribed sequence variant c.1430G>C in exon 14 (p.Gly477Ala) in the gene UBA1. In vitro enzymatic analyses showed that p.Gly477Ala led to both decreased E1 ubiquitin thioester formation and E2 enzyme charging. CONCLUSION: We report a case of a patient of European ancestry with clinical manifestations of VEXAS syndrome associated with a newly identified dysfunctional UBA-1 enzyme variant. Due to the patient's insufficient response to various immunosuppressive treatments, allogeneic hematopoietic stem cell transplantation was performed, which resulted in significant improvement of clinical and laboratory manifestations of the disease.
引用
- Stiburkova B, Pavelcova K, Belickova M, et al. Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome. Arthritis Rheumatol. 2023. PMID: 36762418. doi:10.1002/art.42471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。